Post-COVID-19, India needs to strengthen its pharma R&D ecosystem to tap into emerging drug development opportunities and changing paradigms in the new drug development framework.....

Sanjay Singh, Partner – Deal Advisory, Head of Lifesciences, KPMG in India, identifies new generics opportunities, established manufacturing ecosystem, growing penetration of health insurance and ta...

Sanjay Singh, Partner, Deal Advisory, KPMG India, insists that India must improve self-sufficiency & boost pharma manufacturing for global leadership....